Board
Ms Lucy Turnbull, AO
Chairman
Ms Turnbull has strong links to the healthcare sector, having previously been Chairman of the New South Wales Government's Ministerial Advisory Committee on Biotechnology from 2001-2, a Director of the Sydney Cancer Foundation from 2002-6 and Director and Chair of the Sydney Children's Hospital Foundation from 1993-2000. She is currently on the Board of the Cancer Institute NSW.
Ms Turnbull also has a strong depth of experience in commercial legal practice and investment banking. During her career Ms Turnbull has held a number of high profile positions, including Lord Mayor of the City of Sydney from 2003-2004 and, prior to that, Deputy Lord Mayor of Sydney from 1999-2003.
Ms Turnbull is currently a Board member of urban renewal organisation, the Waterloo Redfern Authority and the Sydney Metropolitan Development Authority. Ms Turnbull is active in the not for profit sector and is currently Deputy Chairman of the Committee for Sydney, a board member of the US Studies Centre at Sydney University and the Centre for Independent Studies. She is also a board member of the Biennale of Sydney and the Redfern Foundation.
Mr Albert Yue-Ling Wong, BCom, (UNSW), F Fin, MSDIA, FAICD
Deputy Chairman
Formerly a stockbroker for 21 years, Mr Wong is a corporate adviser and investment banker with over 28 years experience in the finance industry. He was admitted as a Member of the Australian Stock Exchange in 1988 and was the principal of Intersuisse Limited until 1995 when he established and listed on ASX the Barton Capital group of companies including eStar Online. Mr Wong was also a founding Director of both Pluton Resources Limited and Gujarat NRE Resources NL. Mr Wong is currently Chairman of RIMCapital Limited and Winmar Resources Limited.
Over the years, Mr Wong has been widely involved in philanthropic activities including current directorships on UNSW Foundation Limited (the principal fund raising arm of The University of New South Wales), Ian Thorpe
Mr Martin Rogers, BEng (Chem), BSc
Chief Executive Officer
Mr Rogers is the Managing Director and Chief Executive Officer of Prima BioMed. He has a strong science background, which includes degrees in science and chemical engineering and is currently a member of the management committee of the National Breast Cancer Foundation. Mr Rogers also has strong expertise in the corporate sector, with a focus on the incubation and development of new business ideas. He has previously been involved in the origination of a number of new business concepts and the establishment of internal ventures and external partnerships, including finance concept origination in the corporate banking sector for institutions such as Macquarie Bank.
Dr Richard Hammel, BPharm, MSc, PhD
Non-Executive Director
Dr Hammel is a partner with ProPharma International Partners, a pharmaceutical/biotechnology consulting firm providing a range of business, financial and product development services. He has previously held senior management positions with Glaxo Smith Kline, Connetics Corporation (Vice President for Commercial Development), Matrix Pharmaceuticals Inc. (Vice President Business Development, Sales and Marketing) and has also held several positions at Glaxo Inc, where he has been Director, Professional Affairs; Director, New Business Development; and Director, Marketing Services.
Dr Neil Frazer, MB ChB
Director
Dr Frazer has more than 23 years of drug development experience in multiple therapeutic areas including more than six years of oncology drug development experience. Dr Frazer commenced his medical career as a UK-based anesthetist working in the UK National Health Service and has worked in Europe and in the US conducting Phase I-IV studies, which have led to product registrations in Europe and the US. Prior to joining Prima BioMed, Dr Frazer held senior management roles with Glaxo and Glaxo-Wellcome and Clintrials Research, and had also held executive medical roles with PharmaLinkFHI (eCRO), Shire Pharmaceuticals, Erimos Pharmaceuticals and Chimerix, Inc.
|